The Clinical Effects of Beraprost Sodium on Raynaud's Phenomenon of Progressive Systemic Sclerosis.

DOI 5 References
  • DEMPO Kenichi
    Department of Dermatology, Yokohama City University School of Medicine
  • SASAKI Tetsuo
    Department of Dermatology, Yokohama City University School of Medicine
  • NAKAJIMA Hiroshi
    Department of Dermatology, Yokohama City University School of Medicine

Bibliographic Information

Other Title
  • 全身性強皮症のレイノー現象に対するベラプロストナトリウムの治療効果

Search this article

Abstract

The clinical effects of beraprost sodium, which is the orally available analogue of prostacycline (PGI2), on Raynaud’s phenomenon of progressive systemic sclerosis (PSS) were evaluated. Twenty-one patients with PSS were given an oral dose of either 60 or 120 μg beraprost sodium per day. After 8 weeks of treatment, Raynaud’s phenomenon moderately decreased in thirteen patients (62%). In seven patients (33%), side effects such as headache and a burning sensation of the face were seen, but all the symptoms improved after decreasing the dosage without discontinuing the drug administration. In addition, no significant change in the laboratory findings was seen after the treatment. These results indicate that beraprost sodium can thus serve as an alternative modality in the management of Raynaud’s phenomenon in PSS.

Journal

  • Nishi Nihon Hifuka

    Nishi Nihon Hifuka 57 (1), 80-83, 1995

    Western Division of Japanese Dermatological Association

References(5)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top